Hong Kong Stocks Midday Review | Mixed performance among the three major indices, with the Hang Seng Index up 0.39%; widespread gains in technology stocks, Bilibili up nearly 4%, Tencent up nearly 3%; declines observed in multiple semiconductor stocks, wi

Several technology and internet stocks rose, with Tencent up 2.72% and NetEase-S up 2.06%. Gold stocks declined, with China Gold International Resources falling 4.45% and Zijin Gold International dropping 3.47%. Non-ferrous metal stocks generally fell, with Ganfeng Lithium declining 4.88% and Tianqi Lithium down 4.33%.

Futu NewsMay 19 12:09

Pharmjet Healthcare-B plans to place 3.836 million shares at a discount of approximately 18.01%, raising a net amount of HKD 152 million.

Pharmjet Healthcare-B (02617) announced that on May 19, 2026 (before trading hours), the company entered into a placement agreement with the placement agent. Under the agreement, the placement agent conditionally agreed to act as the company’s placement agent and, on a best-efforts basis, arrange for placees to purchase 3.836 million placement shares at a placement price of HKD 40.83 per share. Assuming no change in the number of issued shares from the date of this announcement to the closing date, the 3.836 million placement shares under the placement will represent approximately 1.24% of the existing issued H shares as of the date of this announcement and 0% of the total existing issued shares.

Sina HK StocksMay 19 08:04

PharmAdvantage-B (02617) plans to place 3.836 million shares at a discount of approximately 18.01%, raising net proceeds of HKD 152 million.

PharmAbcine-B (02617) announced that on May 19, 2026 (before trading hours), the company entered into a placement agreement with the placing agent. Under the agreement, the placing agent conditionally agreed to act as the company’s placing agent and, on a best-efforts basis, arrange for placees to purchase 3.836 million placement shares at a placement price of HKD 40.83 per share.

Zhitong FinanceMay 19 06:37

PharmAbcure (02617.HK) announced exploratory clinical results for its core product, Tienogotinib.

PharmAbcine-B (02617.HK) announced the publication of exploratory clinical results for its core product, Tinenogrel monotherapy and in combination with Atezolizumab, for the treatment of advanced solid tumors in Nature Communications (IF=15.7). The company reported that the objective response rate (ORR) for Tinenogrel monotherapy in Group A reached 16.7%, while the ORR for the combination therapy with Atezolizumab in Group B was 22.6%, both demonstrating anti-tumor activity.

AASTOCKSMay 18 10:09

PharmAbc-B (02617) published exploratory clinical results of its core product, Tengotinib, as a monotherapy and in combination with Atezolizumab for the treatment of advanced solid tumors, in a subsidiary journal of Nature.

Acurant-B (02617) announced the publication of exploratory clinical results for its core product, Tengotinib, as a monotherapy and in combination with Atezolizumab for the treatment of advanced solid tumors, in Nature Communications (IF=15.7).

Zhitong FinanceMay 17 18:44

TRANSTHERA-B: ANNUAL REPORT 2025

HKEXApr 23 22:30 · Announcements